Who
David E. I. Pyott
Director
Company insider
Files Form 4 as: Director, Tarsus Pharmaceuticals; Director, Alnylam Pharmaceuticals; Director, Pliant Therapeutics; Director, BioMarin Pharmaceutical; Director, Avery Dennison; Chairman of the Board and CEO, Allergan; Director, Edwards Lifesciences.
In numbers
- Trades disclosed
- 484
- Buys
- 4
- Sells
- 39
- Bought
- $3.2M
- Sold
- $294.1M
- Companies
- 7
- Companies where not an officer
- 6
- First trade
- 6 Feb 2006
- Last trade
- 15 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 17 Sep 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —201 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —201 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —201 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —201 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,837 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,417 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —806 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,837 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,417 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —806 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,830 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $274K921 at $297.71 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $351K1,175 at $298.91 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,830 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $366K1,222 at $299.87 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $149K495 at $300.72 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $5,14517 at $302.65 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,830 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,830 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $274K921 at $297.71 | filing |
News
Critical Survey: TScan Therapeutics (NASDAQ:TCRX) and Alnylam Pharmaceuticals (NASDAQ:ALNY)ALNY · dailypolitical.com · 22 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) versus Oncocyte (NASDAQ:IMDX) Head to Head ComparisonALNY · dailypolitical.com · 21 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) and TScan Therapeutics (NASDAQ:TCRX) Critical SurveyALNY · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name David E. I. Pyott; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.